InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study

NCT ID: NCT04016324

Last Updated: 2021-11-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-28

Study Completion Date

2020-10-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Post-market clinical follow-up for continued assessment of safety and performance of the InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder Urinary Urge Incontinence Urgency-frequency Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Overactive Bladder Urinary Urge Incontinence Urgency-frequency Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

To characterize proportion of subjects who demonstrate motor or sensory response(s) during lead placement using the InterStim Basic Evaluation Lead.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Basic evaluation

Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.

Group Type OTHER

InterStim Basic Evaluation lead and foramen needle

Intervention Type DEVICE

Commercial devices within their intended use as described in approved Instructions for Use.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

InterStim Basic Evaluation lead and foramen needle

Commercial devices within their intended use as described in approved Instructions for Use.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects 18 years of age or older
2. Candidate for sacral neuromodulation in accordance with the InterStim System labeling
3. Have a diagnosis of overactive bladder (OAB) as demonstrated by either urinary urge incontinence and/or urinary frequency on a 3-day voiding diary
4. Willing and able to accurately complete study diaries, questionnaire, attend visits, and comply with the study protocol
5. Willing and able to provide signed and dated informed consent

Exclusion Criteria

1. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
2. Have implantable pacemakers, or defibrillators
3. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
4. Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic exposure, or radio frequency (RF) energy exposure not included within the scanning conditions provided with the InterStim System labeling
5. Women who are pregnant or planning to become pregnant during participation in the study
6. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
7. Concurrent participation in another clinical study that may add additional safety risks and/or confound study results.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MedtronicNeuro

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

BASIC Clinical Research Study Team

Role: STUDY_DIRECTOR

Medtronic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pinellas Urology

St. Petersburg, Florida, United States

Site Status

Florida Urology Partners

Tampa, Florida, United States

Site Status

Minnesota Urology (Plymouth)

Plymouth, Minnesota, United States

Site Status

Urologic Research and Consulting

Englewood, New Jersey, United States

Site Status

FirstHealth Urogynecology

Hamlet, North Carolina, United States

Site Status

Wright State Physicians

Fairborn, Ohio, United States

Site Status

Prisma Health

Greenville, South Carolina, United States

Site Status

Southern Urogynecology

West Columbia, South Carolina, United States

Site Status

Urology Partners of North Texas

Arlington, Texas, United States

Site Status

Urology of Virginia

Virginia Beach, Virginia, United States

Site Status

University Urology Associates

Toronto, Ontario, Canada

Site Status

Radboud UMC

Nijmegen, , Netherlands

Site Status

The Bristol Urological Institute

Bristol, , United Kingdom

Site Status

The Newcastle upon Tyne Hospitals

Newcastle upon Tyne, , United Kingdom

Site Status

Salford Royal NHS Foundation Trust

Salford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Netherlands United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MDT19002

Identifier Type: -

Identifier Source: org_study_id